Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered smartwatches hunt for stealthy heart condition in stroke survivors

NCT ID NCT07540065

Diagnosis Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using artificial intelligence (AI) along with a smartwatch and a heart monitor patch can find a hidden heart rhythm problem called atrial fibrillation (AF) in people who have had a stroke. AF can cause strokes, but it often comes and goes without symptoms. The trial will compare this AI-assisted approach to standard follow-up care in 400 stroke patients. If it works, it could help doctors start blood-thinning medicine sooner to prevent another stroke.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-guided workflow with smartwatch and ECG patch
What this could lead to
If successful, this could make it easier to detect hidden heart rhythm problems after a stroke, helping doctors start blood thinners earlier to prevent another stroke.
What could go wrong
This trial hasn't started yet, and it's testing a new way of using existing devices. The AI may not improve detection rates as hoped, and the smartwatch or patch might be uncomfortable or unreliable for some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18 years or older who are acutely hospitalized due to ischemic stroke; 2. A 12-lead electrocardiogram upon admission showing sinus rhythm; Exclusion Criteria: 1. Previous diagnosis of atrial fibrillation or flutter; 2. Diagnosis of atrial fibrillation during hospitalization; 3. Pre-existing cardiac implantable electronic device (IVD); 4. Expected inability to attend regular outpatient follow-ups after discharge, or to undergo multiple 14-day ECG recordings; 5. Requires long-term anticoagulant use for other reasons, including but not limited to chronic pulmonary embolism; 6. Known contraindications to non-vitamin K antagonist oral anticoagulants due to comorbidities, including but not limited to end-stage renal disease, severe mitral stenosis due to rheumatic heart disease, or metallic heart valves; 7. Unwilling to sign a participant consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence Atrial fibrillation Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Taiwan University Hospita

    Taipei, 100, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.